1887

Chapter 62 : Parvovirus B19

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Parvovirus B19, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH62-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH62-2.gif

Abstract:

Autonomous parvoviruses capable of helper-virus-independent replication have been isolated from many animal species. The human serum parvovirus B19 was accidentally discovered in 1975 in healthy donor blood used in the development of hepatitis B virus surface antigen diagnostic tests. To date, three B19-type genotypes have been described: types 1 (B19), 2 (A6/K71), and 3 (V9). Disease variation has not been reported amongst the three genotypes (1–3). Bocavirus, another parvovirus, has been associated with pulmonary infection (4). PARV4 has been identified in a parenteral drug abuser, but human disease causation has not been confirmed (5, 6). Recently, a proposal was submitted to the International Committee on Taxonomy of Viruses to reclassify B19 as primate erythroparvovirus type 1. The most frequent clinical presentation of B19 infection is erythema infectiosum, or fifth disease, a common childhood exanthem. Application of sensitive molecular biological and immunological methods to viral diagnosis has allowed recognition of the ever-expanding spectrum of clinical presentation (7).

Citation: Naides S. 2016. Parvovirus B19, p 591-597. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch62
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Electron micrograph of serum from a patient with sickle cell disease and aplastic crisis, showing full (white arrow) and empty (black arrow) nonenveloped, icosahedral viral particles measuring ∼23 nm in diameter, visualized by negative staining with uranyl acetate. Bar, 100 nm (original magnification, ×196,000). Reprinted from reference with permission of the publisher.

Citation: Naides S. 2016. Parvovirus B19, p 591-597. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch62
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

ELISA-based tests showing antibody capture ELISA for anti-B19 IgM antibody (A), antibody capture ELISA for anti-B19 IgG antibody (B), antigen capture ELISA for B19 virus (C), and recombinant or synthetic B19 antigen-based ELISA for detection of B19 antibody (D).

Citation: Naides S. 2016. Parvovirus B19, p 591-597. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch62
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818722.ch62
1. Candotti D, Etiz N, Parsyan A, Allain JP. 2004. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 78:1216912178.[CrossRef].[PubMed]
2. Hokynar K, Norja P, Laitinen H, Palomäki P, Garbarg-Chenon A, Ranki A, Hedman K, Söderlund-Venermo M. 2004. Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J Clin Microbiol 42:20132019.[PubMed].[CrossRef]
3. Nguyen QT, Wong S, Heegaard ED, Brown KE. 2002. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 301:374380.[PubMed].[CrossRef]
4. Martin ET, Kuypers J, McRoberts JP, Englund JA, Zerr DM. 2015. Human bocavirus-1 primary infection and shedding in infants. J Infect Dis 212:516524.[CrossRef].[PubMed]
5. Matthews PC, Malik A, Simmons R, Sharp C, Simmonds P, Klenerman P. 2014. PARV4: an emerging tetraparvovirus. PLoS Pathog 10:e1004036.[CrossRef].[PubMed]
6. Benjamin LA, Lewthwaite P, Vasanthapuram R, Zhao G, Sharp C, Simmonds P, Wang D, Solomon T. 2011. Human parvovirus 4 as potential cause of encephalitis in children, India. Emerg Infect Dis 17:14841487.[CrossRef].[PubMed]
7. Naides SJ. 1999. Infection with Parvovirus B19. Curr Infect Dis Rep 1:273278.[PubMed].[CrossRef]
8. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. 1986. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 58:921936.[PubMed]
9. Blundell MC, Beard C, Astell CR. 1987. In vitro identification of a B19 parvovirus promoter. Virology 157:534538.[PubMed].[CrossRef]
10. Naides SJ,. 2000. Parvoviruses, p 487500. In Specter S, Hodinka RL, Young SA (ed), Clinical Virology Manual. ASM Press, Washington, DC.
11. Poole BD, Karetnyi YV, Naides SJ. 2004. Parvovirus B19-induced apoptosis of hepatocytes. J Virol 78:77757783.[CrossRef].[PubMed]
12. Brunstein J, Söderlund-Venermo M, Hedman K. 2000. Identification of a novel RNA splicing pattern as a basis of restricted cell tropism of erythrovirus B19. Virology 274:284291.[CrossRef].[PubMed]
13. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DA. 1985. Experimental parvoviral infection in humans. J Infect Dis 152:257265.[PubMed].[CrossRef]
14. Cooling LL, Zhang DS, Naides SJ, Koerner TA. 2003. Glycosphingolipid expression in acute nonlymphocytic leukemia: common expression of shiga toxin and parvovirus B19 receptors on early myeloblasts. Blood 101:711721.[CrossRef].[PubMed]
15. Cooling LLW, Koerner TA, Naides SJ. 1995. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis 172:11981205.[PubMed].[CrossRef]
16. Cooling LLW, Zhang DS, Naides SJ, Koerner TAW. 2003. Glycosphingolipid expression in acute nonlymphocytic leukemia: common expression of shiga toxin and parvovirus B19 receptors on early myeloblasts. Blood 101:711721.[CrossRef].[PubMed]
17. Weigel-Kelley KA, Yoder MC, Srivastava A. 2003. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 102:39273933.[CrossRef].[PubMed]
18. Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, Hirabayashi Y, Koyanagi Y, Sasaki T. 2005. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106:34493456.[CrossRef].[PubMed]
19. von Kietzell K, Pozzuto T, Heilbronn R, Grössl T, Fechner H, Weger S. 2014. Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q. J Virol 88:81028115.[CrossRef].[PubMed]
20. Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. 1998. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 72:30183028.[PubMed]
21. Kivovich V, Gilbert L, Vuento M, Naides SJ. 2010. Parvovirus B19 genotype specific amino acid substitution in NS1 reduces the protein's cytotoxicity in culture. Int J Med Sci 7:110119.[PubMed]
22. Kivovich V, Gilbert L, Vuento M, Naides SJ. 2012. The putative metal coordination motif in the endonuclease domain of human Parvovirus B19 NS1 is critical for NS1 induced S phase arrest and DNA damage. Int J Biol Sci 8:7992.[PubMed].[CrossRef]
23. Poole BD, Kivovich V, Gilbert L, Naides SJ. 2011. Parvovirus B19 nonstructural protein-induced damage of cellular DNA and resultant apoptosis. Int J Med Sci 8:8896.[PubMed]
24. Thammasri K, Rauhamäki S, Wang L, Filippou A, Kivovich V, Marjomäki V, Naides SJ, Gilbert L. 2013. Human parvovirus B19 induced apoptotic bodies contain altered self-antigens that are phagocytosed by antigen presenting cells. PLoS One 8:e67179.[CrossRef].[PubMed]
25. Eis-Hübinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE. 1996. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zentralbl Bakteriol 284:232240.[CrossRef]
26. Naides SJ. 1998. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 24:375401.[PubMed].[CrossRef]
27. Naides SJ, Scharosch LL, Foto F, Howard EJ. 1990. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum 33:12971309.[PubMed].[CrossRef]
28. Naides SJ, Field EH. 1988. Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch Intern Med 148:25872589.[PubMed].[CrossRef]
29. Meyer O. 2003. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 70:611.[PubMed].[CrossRef]
30. Klouda PT, Corbin SA, Bradley BA, Cohen BJ, Woolf AD. 1986. HLA and acute arthritis following human parvovirus infection. Tissue Antigens 28:318319.[PubMed]
31. Woolf AD, Campion GV, Klouda PT, Chiswick A, Cohen BJ, Dieppe PA. 1987. HLA and the manifestations of human parvovirus B19 infection. Arth Rheum. 30:S52.
32. Foto F, Saag KG, Scharosch LL, Howard EJ, Naides SJ. 1993. Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. J Infect Dis 167:744748.[PubMed].[CrossRef]
33. Söderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K. 2002. Persistence of human parvovirus B19 in human tissues. Pathol Biol (Paris) 50:307316.[CrossRef]
34. Stahl HD, Seidl B, Hubner B, Altrichter S, Pfeiffer R, Pustowoit B, Liebert UG, Hofmann J, von Salis-Soglio G, Emmrich F. 2000. High incidence of parvovirus B19 DNA in synovial tissue of patients with undifferentiated mono- and oligoarthritis. Clin Rheumatol 19:281286.[PubMed].[CrossRef]
35. Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, Saitoh T, Sawai T, Sugamura K, Sasaki T. 1998. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 95:82278232.[PubMed].[CrossRef]
36. Ray NB, Nieva DRC, Seftor EA, Khalkhali-Ellis Z, Naides SJ. 2001. Human parvovirus B19 induces an invasive phenotype in normal human synovial fibroblasts. Arth Rheum 44:15821586.[CrossRef]
37. Takasawa N, Munakata Y, Ishii KK, Takahashi Y, Takahashi M, Fu Y, Ishii T, Fujii H, Saito T, Takano H, Noda T, Suzuki M, Nose M, Zolla-Patzner S, Sasaki T. 2004. Human parvovirus B19 transgenic mice become susceptible to polyarthritis. J Immunol 173:46754683.[PubMed].[CrossRef]
38. Naides SJ, Weiner CP. 1989. Antenatal diagnosis and palliative treatment of non-immune hydrops fetalis secondary to fetal parvovirus B19 infection. Prenat Diagn 9:105114.[PubMed].[CrossRef]
39. Chorba T , et al 1986. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 154:383393.[PubMed].[CrossRef]
40. Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS. 1989. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 84:11141123.[CrossRef].[PubMed]
41. Frickhofen N, Abkowitz JL, Safford M, Berry JM, Antunez-de-Mayolo J, Astrow A, Cohen R, Halperin I, King L, Mintzer D, Cohen B, Young NS. 1990. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 113:926933.[PubMed].[CrossRef]
42. Langnas AN, Markin RS, Cattral MS, Naides SJ. 1995. Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 22:16611665.[PubMed]
43. Sokal EM, Melchior M, Cornu C, Vandenbroucke AT, Buts JP, Cohen BJ, Burtonboy G. 1998. Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet 352:17391741.[CrossRef].[PubMed]
44. Karetnyi YV, Beck PR, Markin RS, Langnas AN, Naides SJ. 1999. Human parvovirus B19 infection in acute fulminant liver failure. Arch Virol 144:17131724.[PubMed].[CrossRef]
45. Anonymous. 1989. Leads from the MMWR. Risks associated with human parvovirus B19 infection. JAMA 261:14061408.[PubMed].[CrossRef]
46. Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. 1989. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 321:485491.[CrossRef].[PubMed]
47. Wu CG, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MY. 2005. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 45:10031010.[CrossRef].[PubMed]
48. Cohen BJ, Mortimer PP, Pereira MS. 1983. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J Hyg (London) 91:113130.[PubMed].[CrossRef]
49. Anderson LJ, Tsou C, Parker RA, Chorba TL, Wulff H, Tattersall P, Mortimer PP. 1986. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 24:522526.[PubMed]
50. Kajigaya S, Shimada T, Fujita S, Young NS. 1989. A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus. Proc Natl Acad Sci USA 86:76017605.[PubMed].[CrossRef]
51. Patou G, Ayliffe U. 1991. Evaluation of commercial enzyme linked immunosorbent assay for detection of B19 parvovirus IgM and IgG. J Clin Pathol 44:831834.[PubMed].[CrossRef]
52. Bruu A-L, Nordbø SA. 1995. Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19. J Clin Microbiol 33:13631365.[PubMed]
53. Heegaard ED, Qvortrup K, Christensen J. 2002. Baculovirus expression of erythrovirus V9 capsids and screening by ELISA: serologic cross-reactivity with erythrovirus B19. J Med Virol 66:246252.[PubMed].[CrossRef]
54. Pickering JW, Forghani B, Shell GR, Wu L. 1998. Comparative evaluation of three recombinant antigen-based enzyme immunoassays for detection of IgM and IgG antibodies to human parvovirus B19. Clin Diagn Virol 9:5763.[PubMed].[CrossRef]
55. Naides SJ, Howard EJ, Swack NS, True CA, Stapleton JT. 1993. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 168:101105.[PubMed].[CrossRef]
56. Clewley JP, Cohen BJ,. 1995. Investigation of human parvovirus B19 infection using PCR, p 205215. In Clewley JP (ed), The polymerase chain reaction (PCR) for human viral diagnosis. CRC Press, Inc, Boca Raton, Fla.
57. Hicks KE, Beard S, Cohen BJ, Clewley JP. 1995. A simple and sensitive DNA hybridization assay used for the routine diagnosis of human parvovirus B19 infection. J Clin Microbiol 33:24732475.[PubMed]
58. Bonvicini F, Manaresi E, Bua G, Venturoli S, Gallinella GJ. 2013. Keeping pace with parvovirus B19 genetic variability: a multiplex genotype-specific quantitative PCR assay. J Clin Microbiol 51:37533759.[CrossRef].[PubMed]
59. Bergallo M, Merlino C, Daniele R, Costa C, Ponzi AN, Cavallo R. 2006. Quantitative competitive-PCR assay to measure human parvovirus B19-DNA load in serum samples. Mol Biotechnol 32:2329.[CrossRef].[PubMed]
60. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. 1993. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 31:323328.[PubMed]
61. Enders M, Helbig S, Hunjet A, Pfister H, Reichhuber C, Motz M. 2007. Comparative evaluation of two commercial enzyme immunoassays for serodiagnosis of human parvovirus B19 infection. J Virol Methods 146:409413.[CrossRef].[PubMed]

Tables

Generic image for table
TABLE 1

Common clinical presentations of parvovirus B19 infection

Citation: Naides S. 2016. Parvovirus B19, p 591-597. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch62
Generic image for table
TABLE 2

Less common clinical presentations of parvovirus B19 infection

Citation: Naides S. 2016. Parvovirus B19, p 591-597. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch62

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error